Efficacy and Safety of Long-Term Imatinib Therapy

Jun 3, 2015 - Conclusions: Long-term treatment with imatinib may improve the functional class and quality of life. ..... characteristic signs on chest...

3 downloads 0 Views 548KB Size

Recommend Documents

Methods: In two double-blind (DB) studies of early PD and one of advanced PD, ..... Any study-drug-related AEa. 201 (39.3) ..... the online version of this article:.

Apr 25, 2013 - 86Б9% at 36 months), reflecting inhibition of chronic haemolysis. TEs decreased by 81Б8%, with 96Б4% of patients remaining free of TEs. Patients also showed a ..... talizations for a disc prolapse, pneumonia and renal failure, the p

May 19, 2011 - ... burden with a clinically manageable safety profile in patients with b-thalassaemia and ...... Schwartz, G.J., Brion, L.P. & Spitzer, A. (1987) The.

This phase 2 pilot study was conducted to determine the efficacy and safety of imatinib mesylate in patients with c-kit– positive acute myeloid leukemia (AML) refractory to or not eligible for chemo- therapy. Twenty-one patients were en- rolled and

Imatinib has substantially changed the clinical management and improved the prognosis of CML and Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ ALL). Here, we review the pharmacology, mode of action, and pharmacokinetics of imatinib

Dec 8, 2015 - Published by Oxford University Press. ... aSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, ... and colectomy-free rates without increased risk of severe adverse events for active UC.

(pertuzumab and trastuzumab plus taxane) regimen had the highest probability to be the preferred treatment ... was based on trastuzumab and docetaxel not prolonging the PFS or .... treatment regimens were assessed: the TPC (carboplatin and trastuzuma

In the SHARP study, Sorafenib treatment continued until the occurrence of both radiologic progression, as defined using the response evaluation criteria in solid ...

in 64.1%, and portal cavernoma presented in 20.5%. Twenty-eight patients received 200U/kg/d of enoxaparin for at least 6 months. In 39.3% of patients PVT was ...

hypokalemia and hypernatremia, which was effectively treated before ECT administration. Standard laboratory test revealed also elevated fastening glucose ...

Mary Ann Liebert, Inc. DOI: 10.1089/cbr. .... radiation protection instructions. No amino acid infusion was ..... Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the.

Jul 13, 2005 - arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 1979; 51:177–87.

problem for men older than age 50, and in men older than 80 the prevalence from this disorder ... natural treatment, lower urinary tract symptoms, bph cause, dr allen's device, clinical trial. 1. ... Dr. Irwig has confirmed persistence of erectile.

Abstract. The number of cancer patients undergoing dialysis has been increasing, and the number of these patients on chemotherapy is also increasing. Imatinib is an effective and safe therapy for KIT-positive gastrointestinal stromal tumors (GIST), b

Feb 20, 2003 - Jorge Cortes, Patricia Ault, Charles Koller, Deborah Thomas, Alessandra Ferrajoli, William Wierda, hypereosinophilic syndrome. Efficacy of imatinib mesylate in the treatment of idiopathic http://bloodjournal.hematologylibrary.org/conte

Jan 29, 2010 - open-label phase 3 study (ClinicalTrials.gov Identifier: .... dol ER 50 mg or oxycodone HCl CR 10 mg with no ..... Katz WA, Barkin RL. Dilemmas ...

Observations: Patients treated with neoadjuvant ima- ... Kaiser Permanente, Rancho. Cordova ... reduction in the 4 patients who were treated with ima-.

Assessor-Blinded, Controlled Trial. Qian Zhang, PhD1; Chunsheng Li, MD2,3; Fei Shao, MD2; Lianxing Zhao, MD2; Miaomiao Wang, MD2;. Yingying Fang, MD2 ...

(AIRC; MFAG 11817 to T. Negri) and by Fondazione Italiana Ricerca sul Cancro. (FIRC) with a fellowship for M. Tazzari. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereb

Treatment-emergent AEs occurring more frequently for naloxegol vs. UC were abdominal ... to diarrhoea and nine patients owing to abdominal pain. Pain scores and .... perspiration, tremor, mydriasis, piloerection and restless- ness on a scale ...

Aug 19, 2013 - Chen Yao8, Zhi-Gang Zhao9, Ru-Ya Zhang10, Xiang-Ling Wang10, Lei Wang10 and VISION Study Group. Abstract. Background ...... 2002, 25:869–875. 23. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL: Dipeptidyl peptidase-4. (DPP-4)

Jul 27, 2017 - dexamethasone (ixazomib-Rd), was approved in 2015 by the US Food ... by a blinded independent review committee (IRC). ..... 58/170 (34).

Biological treatment, in Crohn's disease, stays at the top of the pyramid treatment .... tory infection after the IV dose, treated with Augmentin, conjunctivitis after VIII ...

Keywords: Pemetrexed, maintenance, lung cancer ... icity profile and clinical efficacy such as pemetrexed ..... either 4 cycles of carboplatin/pemetrexed/bevaci-.